{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-23-000030","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.104033+00:00","generated_at":"2026-06-15T09:28:00.608690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Q1 net loss $20.9M; cash $103.4M; BDTX-1535 update H2 2023; BDTX-4933 IND cleared","bullets":["Cash $103.4M as of March 31, down from $122.8M at year-end 2022; net loss $20.9M vs $25.5M in Q1 2022.","Cash runway expected into Q3 2024.","Phase 1 dose escalation of BDTX-1535 ongoing; clinical update on track for H2 2023; dose-expansion cohorts to open in 2023.","FDA clearance for BDTX-4933 IND; first patient dosing expected in Q2 2023.","Development candidate BDTX-4876 (FGFR 2/3 selective) nominated; company evaluating strategic alternatives for FGFR program."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-23-000030","json":"https://secwatch.observer/filing/0001701541-23-000030.json","markdown":"https://secwatch.observer/filing/0001701541-23-000030.md","text":"https://secwatch.observer/filing/0001701541-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/0001701541-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/bdtx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:28:00.608690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"862c24900d53aa4694926b931837ca246bdf8a16","claim":"Black Diamond Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/0001701541-23-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}